Clinical evaluation of commercial SARS-CoV-2 serological assays in a malaria endemic setting-Reference-Cited by-同舟云学术

Clinical evaluation of commercial SARS-CoV-2 serological assays in a malaria endemic setting

Published:2023-06 Issue: Volume:517 Page:113488
ISSN:0022-1759
Container-title:Journal of Immunological Methods
language:en
Short-container-title:Journal of Immunological Methods

Author:

Dabitao Djeneba,Shaw-Saliba Kathryn,Konate Drissa S.,Highbarger Helene C.,Lallemand Perrine,Sanogo Ibrahim,Rehman Tauseef,Wague Mamadou,Coulibaly Nadie,Kone Bourahima,Baya Bocar,Diakite Seidina A.S.,Samake Seydou,Akpa Esther,Tounkara Moctar,Laverdure Sylvain,Doumbia Seydou,Lane H. Clifford,Diakite Mahamadou,Dewar Robin L.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference25 articles.

1. Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin;Emmerich;Trop. Med. Int. Health,2021

2. False-positive results of enzyme immunoassays for human immunodeficiency virus in patients with uncomplicated malaria;Gasasira;J. Clin. Microbiol.,2006

3. Seroprevalence of SARS-CoV-2 antibodies in Africa: a systematic review and Meta-analysis;Hajissa;Int. J. Environ. Res. Public Health,2022

4. Plasmodium infection induces cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein;Lapidus,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Severe Acute Respiratory Syndrome Coronavirus 2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With Coronavirus Disease 2019;Clinical Infectious Diseases;2024-07-17

2. SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali;International Journal of Infectious Diseases;2024-05

3. Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection;Scientific Reports;2024-04-09

4. Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV Infection;2023-12-15